Table 4 Studies exclusively in... | American Society of Hematology

Table 4

Studies exclusively in relapsed/refractory PTCL

Agents	Patients	Central response review	ORR	CR	PFS (months)	DOR (months)	OS (months)
Romidepsin²⁷	130	Yes	25%	15%	4	17	11.3
Belinostat⁵⁷*	129	Yes	26%	10%	NA	8.3	NA
Pralatrexate²⁸	111	Yes	29%	13%	3.5	10.5	14.5
Bendamustine⁵⁸	60	No	50%	28%	3.6	3.5	6.2
Brentuximab vedotin²⁹†	58	Yes	86%	57%	13.3	12.6	NR
Brentuximab vedotin³⁰‡	34	No	41%	24%	2.6	7.6	NA
Gemcitabine⁵⁹§	20	No	55%	30%	NA	NA	NA
Alemtuzumab⁶⁰	14	No	36%	14%	NA	NA	NA

Agents	Patients	Central response review	ORR	CR	PFS (months)	DOR (months)	OS (months)
Romidepsin²⁷	130	Yes	25%	15%	4	17	11.3
Belinostat⁵⁷*	129	Yes	26%	10%	NA	8.3	NA
Pralatrexate²⁸	111	Yes	29%	13%	3.5	10.5	14.5
Bendamustine⁵⁸	60	No	50%	28%	3.6	3.5	6.2
Brentuximab vedotin²⁹†	58	Yes	86%	57%	13.3	12.6	NR
Brentuximab vedotin³⁰‡	34	No	41%	24%	2.6	7.6	NA
Gemcitabine⁵⁹§	20	No	55%	30%	NA	NA	NA
Alemtuzumab⁶⁰	14	No	36%	14%	NA	NA	NA

PFS, DOR, and OS are all medians in months. DOR, duration of response; NA, not applicable.

Reported in abstract form: ASCO 2013.

ALCL patients only.

Non-ALCL patients; reported in abstract form: Lugano 2013.

Reports only patients with PTCL-NOS; excludes patients reported with mycosis fungoides.